AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05323019 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will continue to receive the therapy that their treating physician felt was appropriate at the time of enrolment in the study, These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical exercise or relaxation.
Study NCT05323019 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal Ketamine (esketamine)
Description: Intranasal Ketamine (esketamine) - participants will receive a dose of 56 mg for a maximum of 2 weeks, followed by 56 mg or 84 twice a week for a total of 8 doses during the 28 -day study
Study NCT05034068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.15% bezaydamine hydrochloride.
Description: 0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.
Study NCT05034068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low power laser with a wavelength of 870 nm
Description: the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2
Study NCT05202535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment.~3x/week on alternate days for 8 weeks at 40-70% of HR Max
Study NCT05202535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
Study NCT04996836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing and Network Analysis
Description: Next Generation Sequencing and Network Analysis will profile genetic and epigenetic abnormalities in blood from patients with BC.
Study NCT05406271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopy
Description: Impantation of hip prosthesis with intraoperative fluoroscopy
Study NCT05887362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Reflexology
Description: Reflexology is a well-known, safe, and noninvasive alternative medicine technique. It alludes to a treatment that is applied to particular areas of the hands and feet. The compression on the hands or feet serves as a sensor linked to particular body areas. These sensors are activated by the reflexology technique to improve blood flow, energize, relax, and maintain homeostasis.
Study NCT06613308 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant immunotherapy combined with chemotherapy
Description: The treatment regimen consisted of a PD-1/PD-L1 monoclonal antibody in combination with a platinum-containing two-agent standard chemotherapy regimen administered every three weeks. Following two to four cycles of therapy, patients who demonstrated no evidence of disease progression were eligible for surgical resection, which was performed within three to four weeks after the conclusion of the last neoadjuvant therapy. Consolidation with a PD-1/PD-L1 monoclonal antibody was initiated within three to eight weeks after surgery and continued every three weeks. The efficacy of the treatment was evaluated according to the irRECIST criteria. Chemotherapy regimens were selected based on tumour histology and investigator judgement. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.
Study NCT06613308 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: A platinum-containing two-agent standard chemotherapy regimen was administered every three weeks. Following a two-to-four-cycle therapy, if the patients were evaluated without progressive disease, patients undergo surgical resection within three to four weeks of the final neoadjuvant treatment. Postoperative adjuvant chemotherapy is then conducted in accordance with the recommended regimen outlined in the 2022 edition of the CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer. The efficacy of the treatment was evaluated in accordance with the RECIST 1.1 criteria.~The chemotherapy regimens were selected based on the tumor histology and the judgement of the investigators, in accordance with the standard clinical practice. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.
Study NCT06613321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory function tests before introduction of vasodilator therapy
Description: Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.
Study NCT06613321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3 month follow up evaluation of response to treatment.
Description: Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.
Study NCT06386159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention or Comprehensive Intervention Combined with Electrical vagus nerve stimulation
Description: Comprehensive intervention includes multidisciplinary collaboration, screening and assessment, oral sensory training, oral motor training, respiratory training, and feeding management. Transcutaneous electrical stimulation of the vagus nerve at the lateral neck was performed by rehabilitation therapists. The cervical vagus nerve accompanies the carotid artery and is located at the groove between the trachea and the sternocleidomastoid muscle, which can be located by touching the carotid pulse. The two electrodes were pasted along the path of the cervical vagus nerve.
Study NCT06386159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Intervention or Comprehensive Intervention Combined with Electrical vagus nerve stimulation
Description: Comprehensive intervention includes multidisciplinary collaboration, screening and assessment, oral sensory training, oral motor training, respiratory training, and feeding management. Transcutaneous electrical stimulation of the vagus nerve at the lateral neck was performed by rehabilitation therapists. The cervical vagus nerve accompanies the carotid artery and is located at the groove between the trachea and the sternocleidomastoid muscle, which can be located by touching the carotid pulse. The two electrodes were pasted along the path of the cervical vagus nerve.
Study NCT06239181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: The patients in the intervention group scheduled for angiography were administered the Beck Anxiety Scale, and then they underwent conscious, deep breathing exercises along with synchronized breathing training. The face-to-face teaching and application of the breathing exercises took an average of 15-20 minutes. Additionally, routine treatment was applied. For both the intervention and control groups, the Beck Anxiety Scale was administered again after the completion of the coronary angiography procedure, once stabilization was achieved.
Study NCT06239181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention/routine procedure
Description: Beck Anxiety Scale was administered to the control group before coronary angiography. No intervention was performed in between. The routine procedure of the hospital continued. Beck Anxiety Scale was administered again after leaving the procedure.
Study NCT05351593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV
Study NCT05351593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given Orally
Study NCT06173518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO1
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells
Study NCT05053971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO
Study NCT05053971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Description: Undergo core needle biopsy
Study NCT05053971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT05363956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salvadora
Description: The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
Study NCT05363956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eucalyptus Oil
Description: The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
Study NCT05382013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Patients will receive treatment of oral avatrombopag 20mg per day for the first 5 days
Study NCT05382013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Liver Support System
Description: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
Study NCT05382013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Liver Support System
Description: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
Study NCT05382013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive internal medical treatment.
Description: Patients will receive comprehensive internal medical treatment.
Study NCT05382013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive internal medical treatment.
Description: Patients will receive comprehensive internal medical treatment.
Study NCT05589220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: Music therapy carried out with MUSIC CARE©
Study NCT05589220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement
Description: NRT: Nicotine Patch, Nicotine Gum
Study NCT05589220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement
Description: NRT: Nicotine Patch, Nicotine Gum
Study NCT05986422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: The treatment period consists of six weeks of daily intake of either Methylprednisolone or placebo (depending on randomization), followed by an additional six weeks of daily intake of open-label Methylprednisolone. During the study, follow-up assessments will be conducted at two points: at week 8 and week 20 from the start of each treatment phase.
Study NCT05986422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: The treatment period consists of six weeks of daily intake of either Methylprednisolone or placebo (depending on randomization), followed by an additional six weeks of daily intake of open-label Methylprednisolone. During the study, follow-up assessments will be conducted at two points: at week 8 and week 20 from the start of each treatment phase.
Study NCT05372107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-80308
Description: AG-80308 Eye Drop Solution
Study NCT06184035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-SN201
Description: Intravenous infusion
Study NCT04654767 — intervention group
Intervention type: OTHER
Intervention: Tissue sampling
Description: Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls.
Study NCT05657418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS107
Description: JS107, i.v., q3w
Study NCT05657418 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS107 combination with Toripalimab
Description: JS107 i.v., q3w combine with Toripalimab
Study NCT05780034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC676
Description: AC676 will be given orally (PO) on a 28-day cycle.
Study NCT05316792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking
Description: 30 min walking on the treadmill and tartan floor
Study NCT06376877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise.
Study NCT06376877 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Description: The sham TMS coil mimics the scalp sensation of real TMS by delivering a small amount of electrical current with a pair of surface electrodes.
Study NCT05664789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N acetyl cysteine
Description: N-acetylcysteine (NAC) is an over-the-counter dietary supplement that is relatively well tolerated and exhibits minimal side effects, even at high dosages. N
Study NCT05664789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT05964920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Two placebo injections one at baseline and one week 3.
Study NCT05964920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.
Study NCT05964920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline + Resistance exercise training
Description: Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
Study NCT05964920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate + Resistance exercise training
Description: Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
Study NCT05607121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: transcranial magnetic stimulation
Study NCT05607121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: transcranial magnetic stimulation
Study NCT05614401 — intervention group
Intervention type: OTHER
Intervention: functional and medical information
Description: 1) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.
Study NCT04664907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videomusic listening
Description: Patients will attend a 8 min videomusic session and questionnaires will be performed before and after this session.
Study NCT06272149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGN-R08b
Description: VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.
Study NCT06405802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-evaluation
Description: Evaluations will be carried out in two different environments: face-to-face in the clinic and remotely using technology. Face-to-face applications and remote evaluations using technology will be repeated once. Face-to-face applications will be made to individuals with low back pain who come to Bozyaka Training and Research Hospital and volunteer to participate in the study. Then, patients will be video-called at home, asked to perform the tests twice as taught, and recorded as a video.
Study NCT06380933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: first received a foot bath with lavender essential oil at 41-42C warm water for 20 minutes for 3 days, then rested for 3 days, and then received routine care for 3 days
Study NCT05926466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 belongs to the chemical class of benzothiazinones, and is a promising antibiotic for the treatment of Tuberculosis. Its mechanism of action is based on the covalent inhibition of the enzyme decaprenylphosphoryl-ß-D-ribose-2'-epimerase (DprE1), which is essential for the cell wall assembly of mycobacteria. . Formation of the covalent adduct between BTZ-043 and DprE1 results in inhibition of cell wall biosynthesis and loss of viability of Mycobacteria Tuberculosis. BTZ-043 has been evaluated in three clinical studies: a phase Ia, First Time in Human study (FTIH), a two-stage phase Ib multiple ascending dose (MAD) and phase IIa monotherapy early bactericidal activity (EBA) study, and a human ADME (Absorption/Distribution/Metabolism/Excretion) study.
Study NCT05926466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline
Description: Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.
Study NCT05926466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.
Study NCT05926466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delamanid
Description: Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.
Study NCT05926466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.
Study NCT05926466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin belongs to the group of fluoroquinolones (FQ). FQs are a mainstay of MDR-TB treatment, and Moxifloxacin is considered the most potent drug in second line MDR-TB therapy, recently reviewed by WHO, with only moderate pre-existing resistance in the community.
Study NCT06344689 — intervention group
Intervention type: OTHER
Intervention: Surgical treatment
Description: Patients underwent surgical treatment of ectropion were included in this study.
Study NCT05762562 — intervention group
Intervention type: OTHER
Intervention: Telerehabilitation with open source platforms
Description: Telerehabilitation with opensource platforms. Patients enrolled were dived into three groups based on their score in SPPB. Each group corresponded to a Program (Pr): • Pr. A is for patients with capable motor skills, Pr. B is for patients with reduced motor skills, • Pr. C is for patients who didn't show having sufficient motor skills to support a TR program. Patients who were included in TrP.A and TrP.B underwent a TR program using OS platforms for 8 consecutive weeks. A specific exercise program for the parkinsonian patients was structured in relation to the individual residual motor skills based on the FITT - frequency/intensity/type/time - protocol.~Twice a week, the activity was performed with the support of a physiotherapist through OS TR platform.~Subjects included in TmP.C participated in an 8-weeks program. A video-call was scheduled once a week to monitor the patient's clinical condition without any exercise program.